What is Precise Bio?
Precise Bio is at the forefront of bio-fabrication, specializing in the development of bio-fabricated organs through an integrated 3D printing and tissue-engineering platform. Their proprietary technology enables the scalable and repeatable production of organs using a patient's own cells. This breakthrough addresses critical needs across multiple healthcare domains, including ophthalmology, cardiology, orthopedics, and dermatology. By equipping clinicians with advanced tissue engineering science and proprietary bio-printing capabilities, Precise Bio is poised to capture significant market opportunities and revolutionize organ replacement therapies.
How much funding has Precise Bio raised?
Precise Bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Precise Bio?
The recent large-scale, late-stage funding indicates that Precise Bio is likely entering a phase of significant expansion and commercialization. This strategic investment will probably fuel the scaling of their manufacturing processes, further research and development into new organ applications, and the expansion of their clinical partnerships. The company's focus on patient-specific cell-based organs positions it as a key player in the future of regenerative medicine, aiming to overcome the limitations of traditional organ transplantation and address the growing demand for viable treatment options.
See full Precise Bio company page
